title: [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
abstract: BACKGROUND
  The relationship between genetically determined polymorphic oxidation and acetylation and susceptibility to some disease was aroused much interest. The aim of our study was to evaluate whether patients with hyperthyreosis differ from healthy persons in their ability to oxidize sparteine and acetylate sulphadimidine as model drugs. Oxidation and acetylation were estimated in 48 patients with hiperthyreosis.
  
  
  METHODS
  The control group consisted of 160 healthy volunteers for comparison of oxidation phenotype and 60 healthy volunteers for comparison of acetylation phenotype. The phenotyping of oxidation revealed two distinct populations among 40 patients with hyperthyreosis: 38 persons (95%) were extensive metabolizers (EM) of sparteine and 2 persons (5%) was poor metabolizers (PM). In 160 healthy persons (91.2%) were EM and 14 persons (8.8%) were PM. The difference between frequency distribution of PM and EM in healthy persons and in patients with hyperthyreosis was not statistically significant.
  
  
  RESULTS
  The phenotyping of acetylation showed among 48 patients with hyperthyreosis 8 persons (13%) were rapid acetylators (RA) and 40 persons (87%) were slow acetylators (SA). In 60 healthy volunteers the phenotype of rapid acetylation was observed in 31 persons (51%) and slow acetylation in 29 persons (49%). Relative risk (odds ratio) of development of thyroid diseases was 5.34 times higher for SA in comparison to RA. The prevalence of SA among patients with hyperthyreosis in comparison to healthy volunteers was statistically significant (p < 0.0002).
  
  
  CONCLUSIONS
  The results of our study may suggest that slow acetylation phenotype is associated with increased risk of the development of hyperthyreosis.
authors.affiliation: Department of Clinical Pharmacology, Medical University, Wroclaw.
authors.forename: Piotr
authors.initials: P
authors.lastname: Milejski
authors.forename: Krystyna
authors.initials: K
authors.lastname: Orzechowska-Juzwenko
authors.forename: Przemysław
authors.initials: P
authors.lastname: Niewiński
authors.forename: Magdalena
authors.initials: M
authors.lastname: Hurkacz
authors.forename: Henryk
authors.initials: H
authors.lastname: Czarnik-Matusewicz
authors.forename: Zdzisław
authors.initials: Z
authors.lastname: Forkasiewicz
authors.forename: Janusz
authors.initials: J
authors.lastname: Dawiskiba
authors.forename: Wiktor
authors.initials: W
authors.lastname: Bednarz
authors.forename: Paweł
authors.initials: P
authors.lastname: Domosławski
mesh_terms: D000107:Acetylation; D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000235:genetics* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D010641:Phenotype; D011110:Polymorphism, Genetic; D013034:Sparteine / Q000378:metabolism; D013418:Sulfamethazine / Q000378:metabolism
chemical_list: D013034:Sparteine; D013418:Sulfamethazine